Perspectives on leadership, governance, and partnership integrity
Sabine Hutchison writes about the structural patterns that shape clinical development outcomes, and the leadership decisions that determine whether programs hold under pressure.
-
When Does the Patient Leave the Room? A Leadership Question for Biotech Sponsors in Clinical Development
Patient focus in clinical development is the deliberate practice of re-centring patient impact in leadership decisions, governance structures, and operational trade-offs throughout the lifecycle of a trial. It…
-
The Most Expensive Assumption in Clinical Development: That Alignment Is Already There
Alignment in a clinical trial partnership is the shared understanding of priorities, roles, decision rights, and expectations that allows sponsors and their vendor partners to execute as a…
-
Why Your CRO Is Not Telling You What You Need to Know, And What That Costs Your Trial
CROs often withhold early signals of risk, resource pressure, or operational misalignment from sponsors. This is not because they have decided to be dishonest. It is because past…
-
When Communication Breaks Down in Clinical Trials, Leadership Has Already Failed
Communication breakdown in a sponsor-CRO relationship is the visible consequence of alignment that was never tested. By the time it becomes visible as a missed deadline, a difficult…
-
Why Sponsor-CRO Governance Models Break Down at Execution, Not Strategy
A sponsor-CRO governance model is the operating architecture that defines how decisions are made, how accountability is distributed, and how issues are escalated between a sponsor and its…
-
Accountability Does Not Transfer With the Contract: What Biotech Sponsors Need to Know About CRO Delegation
Sabine Hutchison, Co-CEO of Seuss+, argues that accountability for clinical trial outcomes cannot be delegated along with the execution work. When a biotech sponsor contracts a CRO to…